

Published in final edited form as:

Science. 2021 August 20; 373(6557): 926–931. doi:10.1126/science.abj0089.

Malaria infection and severe disease risks in Africa

Robert S Paton^{#1,*}, Alice Kamau^{#2,3,*}, Samuel Akech², Ambrose Agweyu², Morris Ogero², Charles Mwandawiro⁴, Neema Mturi⁵, Shebe Mohammed⁵, Arthur Mpimbaza⁶, Simon Kariuki⁷, Nancy A Otieno⁷, Bryan O Nyawanda⁷, Amina F Mohamed^{8,9}, George Mtove¹⁰, Hugh Reyburn⁹, Sunetra Gupta¹, Philip Bejon^{3,5}, José Lourenço¹, Robert W Snow^{2,3}

¹Department of Zoology, University of Oxford, Oxford, UK

²Kenya Medical Research Institute (KEMRI) - Wellcome Trust Research Programme, Nairobi, Kenya

³Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK

⁴Eastern and Southern Africa Centre of International Parasite Control, Kenya Medical Research Institute (KEMRI), Nairobi, Kenya

⁵Kenya Medical Research Institute (KEMRI) - Wellcome Trust Research Programme, Kilifi, Kenya

⁶Child Health and Development Centre, Makerere University, College of Health Sciences, Kampala, Uganda

⁷Kenya Medical Research Institute (KEMRI) - Centre for Global Health Research, Kisumu, Kenya

⁸Kilimanjaro Christian Medical Centre/Joint Malaria Programme, Moshi, Tanzania

exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. This author manuscript is distributed under the terms of the Creative Commons Attribution license (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. This work is licensed under a [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/) International license.

*Corresponding authors. robert.paton@zoo.ox.ac.uk (R.S.P) and akamau@kemri-wellcome.org (A.K).

Author contributions:

R.W.S. conceived the study. R.S.P. analyzed and interpreted the data and A.K., J.L., S.G. and R.W.S. provided inputs. S.A., A.A., M.O., C.M., N.M., S.M., A.M., S.K., N.A.O., B.O.N., A.F.M., G.M., H.R. and P.B. managed the pediatric ward surveillance and the community parasitological surveys. R.S.P., A.K., J.L. and R.W.S. wrote the first draft of the paper and the supplementary materials. All authors critically revised successive drafts of the paper and approved the final version, as submitted.

Competing interests

The authors declare no competing interests.

Ethics statement

Hospital surveillance: Kilifi A-C: Kenya Medical Research Institute/Scientific and Ethics Review Unit (KEMRI-SERU) IRB numbers 1433, 3057, 3149; Siaya A-C: KEMRI SERU IRB numbers 1801 & 2558; CDC Atlanta approval 3308 & 6543; Busia, Kakamega, Vihiga: KEMRI-SERU IRB numbers 2465 and 3459; Bungoma and Homa Bay: KEMRI SERU IRB number 3771 and MoH approval PPB/ECCT/19/06/03/2019(128); Jinja, Tororo, Apac, Mubende and Kabale: surveillance included collection of routine hospital data approved by the CDC as public health surveillance/non-research (NCEZID 031416), and approved by the Director General of Health Services, Ministry of Health, Uganda; Muheza: The study was approved by the ethics committees of the National Institute for Medical Research, Tanzania, and the London School of Hygiene and Tropical Medicine. Community parasite surveys: Kilifi A and B: KEMRI-SERU IRB number 3149; Kilifi C KEMRI-SERU IRB number 3592; Siaya A-C: KEMRI-SERU IRB numbers 1801 & 2558 and CDC Atlanta approval 3308 & 6543 (repeat cross-sectional surveys; Busia, Kakamega, Vihiga, Bungoma, and Homa Bay school surveys 2014 to 2019 IRB numbers KEMRI SERU 2675, 2801 and 3822). Apac, Kabale, Mubende, Jinja, and Tororo 2019 school surveys Vector Control Division Research Ethics Committee, MoH, Kampala: VCDREC/117. Written informed consent and assent was sought from all participants or from parents and guardians of children enrolled in the community- and school-based malaria parasite surveys undertaken during this study. Data obtained during hospital admissions were part of routine clinical surveillance for which IRB approval was sought; it was accepted that patient-level consent was not required.

⁹London School of Hygiene and Tropical Medicine, London, UK

¹⁰National Institute for Medical Research, Amani Research Centre, Muheza, Tanzania

These authors contributed equally to this work.

Abstract

The relationship between community prevalence of *Plasmodium falciparum* and the burden of severe, life-threatening disease remains poorly defined. To examine the three most common severe malaria phenotypes from catchment populations across East Africa, we assembled a dataset of 6506 malaria admissions in children aged 3 months to 9 years from 2006 to 2020. Admissions were paired with data from community parasite infection surveys. A Bayesian procedure was used to calibrate uncertainties in exposure (parasite prevalence) and outcomes (severe malaria phenotypes). Each 25% increase in prevalence conferred a doubling of severe malaria admission rates. Severe malaria remains a burden predominantly among young children (3 to 59 months) across a wide range of community prevalence typical of East Africa. This study offers a quantitative framework for linking malaria parasite prevalence and severe disease outcomes in children.

Keywords

Malaria; *Plasmodium falciparum* ; severe malaria; anaemia; cerebral malaria; Africa

Plasmodium falciparum causes one of the most deadly, preventable parasitic diseases in Africa. Our understanding of the relationship between parasite exposure, clinical immunity, and malaria mortality is limited by lack of empirical evidence. The attribution of malaria deaths in Africa continues to rely on sparse, outdated information derived from interviews with bereaved relatives (1–3). These methods lack sensitivity and specificity in the absence of confirmatory clinical and parasitological examinations (4). Modelled interpolations on predicted age patterns of malaria mortality have been met with skepticism (5). An alternative source of information is age patterns of severe, potentially life-threatening malaria admissions to hospitals; we use these data to investigate the relationship between community prevalence of *Plasmodium falciparum* and the burden of severe, life-threatening disease.

During the 1990s and early 2000s, ecological analyses were undertaken at various hospital sites to define the age-specific rates of hospitalization from communities with known levels of parasite exposure (6) or proxies of transmission intensity based on temperature-related effects of altitude on transmission (7). Age and clinical phenotypes of severe malaria varied by transmission intensity, such that disease incidence declined rapidly in young children in areas of high transmission in which disease presentations were dominated by severe malaria anaemia (SMA). By contrast, disease incidence declined more slowly with age under conditions of low transmission intensity. Under such conditions, cerebral malaria (CM) was proportionally more common than in areas of high transmission. A historical controversy (8–11) regarding the effects of altering natural parasite exposure, immunity, and the medium- to long-term impacts of vector control and chemoprevention (12–15) was

reignited by the observation that across a wide range of transmission settings common to Africa at that time, overall rates of severe malaria among children aged <10 years appeared similar.

Despite major increases in the coverage of control activities across Africa (16) and a changing landscape of infection prevalence (17), there have been no large-scale epidemiological descriptions of the rates of severe malaria among African children in the past 20 years. Understanding how changes in community parasite prevalence alters the rate and age distribution of children hospitalized with severe malaria is essential for optimizing and predicting the impact of malaria control efforts. Given the scarcity of detailed time series data that indicate how interventions lower transmission and reduce the malaria burden (18), comparing and contrasting data patterns (e.g., age patterns) from sites with different malaria ecologies presents an opportunity to infer what transitioning between different transmission regimes might represent in terms of the rate and age distribution of severe malaria cases.

To define the incidence of pediatric severe malaria admissions against community-based levels of parasite prevalence (age-standardised *Plasmodium falciparum* parasite rate, $PfPR_{2-10}$), we analysed active surveillance data from 13 hospitals in East Africa. These hospitals served 26 communities over 35 time-site specific periods spanning 2006 to 2020 (supplementary materials section 1, fig. S1, and table S1) in which community-based malaria parasite prevalence was recorded (supplementary materials section 1 and table S2). The dataset contains 924 months of hospital observations and 833,864 child-years of community risk across the 35 time-specific catchment areas between 2006 and 2020. A total of 6506 malaria admissions in children aged 3 months to 9 years were used to define severe malaria. The 35 time-site locations represent the range of contemporary malaria ecologies common to the subregion, from historically negligible transmission as determined by parasite prevalence ($PfPR_{2-10} < 1\%$) at Kabale (Uganda) to high transmission sites ($PfPR_{2-10} > 67\%$) at Bungoma, Busia, Siaya (Kenya), and Muheza (Tanzania) (table S2).

The rates of three common severe malaria phenotypes—severe malaria anaemia (SMA), respiratory distress (RD) and cerebral malaria (CM)—were modelled for each of the 35 time-site periods. A Bayesian regression model was implemented with propagated uncertainty in parasite prevalence (supplementary materials section 2.1) and syndrome reporting (supplementary materials section 2.2) to define the relationship between the time-matched, age-standardized diagnostic-corrected parasite prevalence and minimum community-adjusted severe malaria rates per 1000 children per annum (p.a.) (supplementary materials section 1). For a given time-site, the number of malaria admissions for each severe phenotype (or for all three combined) was modelled with three model forms: intercept-only, log-linear, and three-parameter log-logistic models. These model forms were compared using the difference in model deviance information criterion (DIC) (19) to test the hypothesis that severe malaria rates were independent of a linear or asymptotic (sigmoidal) function of community parasite prevalence. Each model form was fitted with both a Poisson and negative binomial distribution; the latter accounts for overdispersion in counts of admitted children (supplementary materials section 1). Model outputs are reported

as the median of the Bayesian posterior estimates, with uncertainty described using highest density intervals (HDIs).

Admission rates of severe malaria increased log-linearly with community parasite prevalence (Fig. 1). Because admission counts were overdispersed, a negative binomial distribution was a better fit than a Poisson ($DIC = 1716$). A log-linear form for $f(P\text{PR}_{2-10})$ was favoured over a log-logistic despite an identical DIC, because more complex functional forms with more parameters must be justified by a considerable reduction in the DIC. An intercept-only formulation performed poorly compared with the log-linear structure ($DIC = 22$) (table S4). The selected model suggests that with every 25% increase in community parasite prevalence, annual severe malaria admission rates approximately doubled (2.06 HDI: 1.58 to 2.73). This manifested as an estimated severe malaria admission rate of 1.02 per 1000 children p.a. (HDI: 0.84 to 1.28) at 25%, 2.10 per 1000 children p.a. (HDI: 1.61 to 2.95) at 50%, and 4.33 per 1000 children p.a. (HDI: 2.67 to 7.79) at 75% community parasite prevalence (Fig. 1). The model estimated that in the absence of any prevalence ($P\text{PR}_{2-10} = 0$), there would be a background rate of 0.49 (HDI: 0.34 to 0.74) annual admissions of severe malaria phenotypes per 1000 children p.a. Here, $P\text{PR}_{2-10} = 0$ was interpreted as a scenario characterized by either low survey power in detecting parasitaemia or instances in which infection was acquired outside the study area.

We examined individual relationships between incidences of SMA, RD, CM, and community parasite prevalence. Admission rates of SMA were positively associated with community parasite prevalence (Fig. 2A). The best-fitting model described the number of SMA admissions with a negative binomial distribution ($DIC = 225.1$), indicating overdispersion. A sigmoidal curve was the best-fitting functional form for $f(P\text{PR}_{2-10})$, with a lower DIC than either a log-linear ($DIC = 13.4$) or an intercept-only function ($DIC = 39.7$) (table S4). The effect of community parasite prevalence on SMA admissions was multiphasic; admission rates were very low when community prevalence was low and then increased sharply towards an asymptote. With higher parasite prevalence, the model fit had higher uncertainty, entertaining a range of asymptotic admission rates when community prevalence was high. There was a positive log-linear correlation between rates of RD (a marker of severe malaria indicating acidotic breathing) and community parasite prevalence, but with high uncertainty (Fig. 2B and table S4). Admission counts were overdispersed, with the negative binomial distribution favored for explaining the counts ($DIC = 525.3$). There was no correlation between parasite prevalence and rare presentations of CM using any model forms (Fig. 2C), although rates were still overdispersed ($DIC = 104.1$). CM was estimated to occur at a low, constant rate (0.19 per 1000 children p.a.) (HDI: 0.13 to 0.30) for all values of $P\text{PR}_{2-10}$.

To explore the relationship between admissions rate, age, and parasite prevalence in more detail, a model that described admissions as continuous functions of both parasite prevalence and age was developed (supplementary materials section 2.3). This model estimated that if community parasite prevalence was lower than 15.9% (HDI: 14.1 to 17.6), a uniform distribution was an adequate description of the data (Fig. 3) - i.e., site with low transmission show little or no age dependence in severe malaria admissions (fig. S2). Determining this cutoff does not preclude age dependence in admissions below this level but may reflect

a lack of statistical power to identify age dependencies as severe malaria becomes rare at low-prevalence sites. Above a community parasite prevalence of 15.9%, the peak age of admission was predicted to decrease from 15.24 months (HDI: 12.18 to 18.24) at a PPR_{2-10} of 25% to 3.32 months (HDI: 3.05 to 4.02) at 75%. This shift in peak age was concomitant with an approximate four-fold increase (4.22; HDI: 2.62-7.03) in admissions across the same change in parasite prevalence (25 to 75%).

Within our data series, Tororo, Homa Bay, and Kilifi North (fig. S1) were sampled more than once, with subsequent visits coinciding with declines in community prevalence. Data obtained from these repeatedly measured sites all support the model prediction that rapid or systematic longer-term reductions in parasite prevalence have not led to an overall increase in severe malaria incidence in children aged 5 to 9 years, relative to those aged less than 5 years. For instance, we estimated that between the first data collection period in Tororo A (2012 to 2013) and the follow-up data gathered later (2017 to 2019), community prevalence declined from 64.1% (HDI: 60.7 to 67.6) to 7.0% (HDI: 4.6 to 9.6). Severe malaria admissions were reduced from 4.97 (HDI: 4.27 to 5.49) per 1000 children p.a. to 1.02 (HDI: 0.71 to 1.27). As explored in our age-dependent model, a community parasite prevalence this low was not associated with a detectable increase in the age of admission.

We applied a statistical modeling approach to an empirical data series from 35 time-site periods to provide a data-driven analysis of the functional relationships between age, immunity, disease, and exposure. The varying age distributions of severe malaria admissions from low to high intensities of community prevalence have been described previously (14, 20–22) and are consistent with expected patterns of age, exposure, and acquisition of immunity (23, 24). In our analyses, we found a strong positive association between community parasite prevalence and the admission rate of severe malaria. Each 25% increase in community parasite prevalence conferred an approximately 2-fold increase in severe malaria admission rate, accompanied by a shift in the peak rate of admissions towards younger children. In the setting with the lowest transmission intensity, the mean age of severe malaria (43.68 months) was twice as high as that in the highest transmission settings (20.88 months), though the overall rates among children aged 3 months to 9 years were considerably lower in the low-transmission settings.

Given the declining rates of SMA and RD admissions with declining community parasite prevalence (Fig. 2, A and B) versus the apparent constant rate of CM admission rates across all transmission settings, CM inevitably accounts for an increasing proportion of severe malaria cases under low transmission. However, the rates of CM were very rare as there were only 135 cases of CM in our data, reducing the power and precision to examine the relationship between the rates of CM and parasite prevalence.

Our results show that severe, life-threatening malaria remains concentrated predominantly among younger children (3 to 59 months) regardless of transmission intensity, with a slight shift towards older children in low-transmission settings. However, this does not appear to translate to any equivalence or increased lifetime risks. The ecological analysis presented here suggests that few early lifetime infections might still confer some level of functional immunity to severe malaria before age 6 under all endemic settings (Fig. 3) (25–27).

Children under 5 years continue to be the focus of disease prevention control in East Africa; SMA remains the primary severe disease phenotype requiring hospital management, and CM is a rare occurrence. Under endemic range of malaria that characterizes East Africa today, the composite admission rate of all severe malaria phenotypes changed log linearly with community prevalence. Although there was no evidence of an inverse relationship or plateau in rates when parasite prevalence was high, as previously inferred (6, 14), this relationship cannot be ruled out but is unlikely given the current range of parasite prevalence. Rates of severe malaria anaemia were asymptotic at high levels of malaria transmission ($PPR_{2-10} > 75\%$). The selection of the log-logistic form over the log-linear function ($\text{DIC} = 13.4$) makes it unlikely that this saturation in admissions is solely an artifact of underestimated rates at a few high-prevalence sites. The consistency in rates of CM across transmission settings indicates that associated clinical immunity is acquired in a different way than in other pediatric phenotypes.

Ecological analyses, such as the one presented here, come with unavoidable caveats. The data from each of the sites presented are a product of a diverse range of past transmission intensities, mitigation strategies, and population structures. This can only be resolved through detailed longitudinal data, which are rare in Africa (28, 29). We have defined parasite exposure as the experience of children in their respective communities at the time their disease profiles were defined. The epidemiology of severe malaria should be reconciled across contemporary malaria ecologies in the subregion; however, this does not capture lifetime parasite exposure. Older children may have been exposed to historical transmission that would have influenced their acquisition of a functional immune response not represented by current levels of transmission intensity. Furthermore, a mixture of endemicity and intervention could explain heterogeneity. With a few exceptions such as donor-driven subnational use of indoor residual spraying (IRS), long-lasting insecticidal nets (LLINs) remain the mainstay of the subregional effort to reduce malaria parasite prevalence in East Africa, as well as throughout the sites included in the present analysis where LLIN coverage was well below universal for children at risk (table S1). Combined attacks on the *P. falciparum* through increased use of LLINs, chemoprevention, and additional vector control efforts with IRS have been shown to rapidly reduce parasite prevalence (30–32). In addition, prompt diagnosis and effective treatment of early-stage disease will affect the progression and rates of severe malaria hospitalization (33). Secondary data from national household surveys of fever treatment, undertaken every 3 to 5 years, lacked the precision necessary to accurately reflect the influence of early treatment on malaria hospitalization at the spatial and temporal scale of our study. To address this limitation, high spatiotemporal survey data will be required in future models relating transmission intensity to rates of severe malaria in Africa. Additionally, the number of severe disease cases reported here may not be representative of all cases, as an unknown proportion of life-threatening infections may not reach the formal health care system. This study was conducted in populations with easy geographic access to hospitals and as such the results may not be generalizable to other settings in which there is limited access to hospital care. Even so, we have provided a quantitative framework for linking community transmission intensity of malaria and its manifestation in the form of severe disease outcomes in children.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The authors are grateful to the many people who have supported the clinical surveillance and parasitological surveys in respective catchment sites over the past 15 years notably at: Kilifi (P. Njuguna, A. Nyaguara, C. Ngetsa, K. Awuondo, E. Otieno, J. Wambua, G. Mwambingu, C. Newton, J. Berkeley, K. Maitland, T. Williams, and A. Scott); Busia, Bungoma, Homa Bay, Kakamega and Vihiga hospitals as part of the Clinical Information Network (CIN) (M. English, F. Were, P. Ayieko, G. Irimu, J. Aluvaala, C. Khazenzi, L. Isaaka, M. Chepkirui, G. Mbevi in collaboration with the Ministry of Health and S. Njenga, C. Omondi and J. Kihara for school parasite surveys in the same areas); Siaya (C. Nyundo, M. Desai, S. Khagayi, C. Odera, F. ter Kuile, R. Brieman, D. Feikin and A. Samuels); sites in Uganda (J. Kapisi, J. F. Namuganga, D. Rutazaana, J. Opyigo, G. Dorsey, S. Staedke, M. Lamorde, C. Maiteki-Sebuguzi, L. Mugenyi, S. Kigozi, A. Rehman, C. Chandler, J. Okiring, R. Male, A. Sserwanga); Muheza (F. Mtei, C. Drakeley, D. Ishengoma). We also appreciate the general support from the KEMRI-Wellcome Trust programme for GIS matching of admissions to populations at risk (D. Kyalo, V. Alegana, E. Mumo). This research was funded in whole or in part by Wellcome Trust (212176/Z/18/Z), a cOAlition S organization. The author will make the Author Accepted Manuscript (AAM) version available under a CC BY public copyright license.

Funding

R.W.S received support as part of the Wellcome Trust Principle Research Fellowships (212176/Z/18/Z) which also provided support for R. S.P and A.K. Surveillance of Busia, Kakamega and Vihiga has been supported by funds from the Wellcome Trust (097170 and 207522), awarded to M. English under the Senior Fellowship and the Kenya Major Overseas Programme, Wellcome Trust core grant (092654). CIN is partly supported by an award to AA from the FCDO/MRC/NIHR/Wellcome Trust Joint Global Health Trials Scheme (MR/R006083/1). Surveillance at Kilifi has been supported by the Wellcome Trust since 2006 under core award for the East African Major Overseas Programme (077092, 092654 and 203077/Z/16/Z). Surveillance in Busia, Bungoma, and Homa Bay (from 2019 to 2020) received support from the CDC Foundation, through funding from the World Health Organization for the RTS,S evaluation (project requisition number 2018/854999); this also supports S.A. Hospital surveillance in Uganda has been supported by the President's Malaria Initiative, U.S. Agency for International Development, under the terms of an Interagency Agreement with the Centers for Disease Control and Prevention (cooperative agreement numbers: 1U51CK000117 & 5NU2GGH001744-02-00). Surveillance at Siaya was supported by core funding provided by the Centers for Disease Control and Prevention (cooperative agreement number 5U01GH000048). Surveillance at Muheza was supported by core funding provided by the European Commission (Europaaid) (SANTE/2004/078-607). A.K. is supported by the DELTAS Africa Initiative (DEL-15-003). The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences (AAS) Alliance for Accelerating Excellence in Science in Africa that is supported by the New Partnership for Africa's Development Planning and Coordinating Agency with funding from the Wellcome Trust (107769/Z/15/Z) and the UK government. Authors affiliated with the KEMRI-Wellcome Trust Programme in Kenya are grateful for the support from the Wellcome Trust to the core award for the East African Major Overseas Programme (203077/Z/16/Z). C.M., S.K., B.O.N., and N.A.O. are grateful for continued support from KEMRI. J.L. was supported by a research lectureship by the Department of Zoology, University of Oxford.

Data and material availability

Data used in this analysis has been curated and uploaded to the Harvard Dataverse (34). Correspondence and requests for materials should be addressed to the KEMRI Wellcome Data Governance Committee (dgc@kemri-wellcome.org). These data are available through a formal requesting process to the KEMRI Institutional Data Access/Ethics Committee. Guideline details can be found on the KEMRI Wellcome website (<https://kemri-wellcome.org/about-us/#ChildVerticalTab15>). All codes associated with the current submission can be found on GitHub (https://github.com/abj0089/Malaria_Project/tree/1.0) and Zenodo (35).

References and Notes

1. Murray CJ, et al. Global malaria mortality between 1980 and 2010: a systematic analysis. *Lancet*. 2012; 379 :413–431. DOI: 10.1016/S0140-6736(12)60034-8 [PubMed: 22305225]
2. Streatfield PK, et al. Malaria mortality in Africa and Asia: evidence from INDEPTH health and demographic surveillance system sites. *Glob Health Action*. 2014; 7 :25369 doi: 10.3402/gha.v7.25369 [PubMed: 25377329]
3. Weiss DJ, et al. Mapping the global prevalence, incidence, and mortality of *Plasmodium falciparum*, 2000–17: a spatial and temporal modelling study. *Lancet*. 2019; 394 :322–331. DOI: 10.1016/S0140-6736(19)31097-9 [PubMed: 31229234]
4. Herrera S, et al. A systematic review and synthesis of the strengths and limitations of measuring malaria mortality through verbal autopsy. *Malar J*. 2017; 16 :421. doi: 10.1186/s12936-017-2071-x [PubMed: 29058621]
5. White N, Dondorp A, Faiz A, Mishra S, Hien T. New global estimates of malaria deaths. *Lancet*. 2012; 380 :559–560. DOI: 10.1016/S0140-6736(12)61321-X
6. Snow RW, et al. Relation between severe malaria morbidity in children and level of *Plasmodium falciparum* transmission in Africa. *Lancet*. 1997; 349 :1650–1654. DOI: 10.1016/S0140-6736(97)02038-2 [PubMed: 9186382]
7. Reyburn H, et al. Association of transmission intensity and age with clinical manifestations and case fatality of severe *Plasmodium falciparum* malaria. *JAMA*. 2005; 293 :1461–1470. doi: 10.1001/jama.293.12.1461 [PubMed: 15784869]
8. Dobson MJ, Malowany M, Snow RW. Malaria control in East Africa: the Kampala Conference and the Pare-Taveta Scheme: a meeting of common and high ground. *Parassitologia*. 2000; 42 :149–166. [PubMed: 11234325]
9. Garnham P. Modern concepts in malaria control. *J R Sanit Inst*. 1949; 69 :617–625. [PubMed: 18148512]
10. Wilson DB. Implications of malarial endemicity in East Africa. *Trans R Soc Trop Med Hyg*. 1939; 32 :435–465. DOI: 10.1016/S0035-9203(39)90062-3
11. Wilson DB, Garnham PCC. A review of hyperendemic malaria. *Trop Dis Bull*. 1950; 47 :677–698. [PubMed: 14788273]
12. Lengeler C, Smith TA. Focus on the effect of bednets on malaria morbidity and mortality. *Parasitol Today*. 1997; 13 :123–124. DOI: 10.1016/S0169-4758(97)84870-3 [PubMed: 15275117]
13. Molineaux L. Malaria and mortality: some epidemiological considerations. *Ann Trop Med Parasitol*. 1997; 91 :811–825. DOI: 10.1080/00034983.1997.11813207 [PubMed: 9625938]
14. Snow RW, Marsh K. The consequences of reducing transmission of *Plasmodium falciparum* in Africa. *Adv Parasitol*. 2002; 52 :235–264. DOI: 10.1016/S0065-308X(02)52013-3 [PubMed: 12521262]
15. Trape JF, Rogier C. Combating malaria morbidity and mortality by reducing transmission. *Parasitol Today*. 1996; 12 :236–240. DOI: 10.1016/0169-4758(96)10015-6 [PubMed: 15275204]
16. WHO. World malaria report 2020: 20 years of global progress and challenges. 2020. www.who.int/publications/i/item/9789240015791
17. Snow RW, et al. The prevalence of *Plasmodium falciparum* in sub-Saharan Africa since 1900. *Nature*. 2017; 550 :515–518. DOI: 10.1038/nature24059 [PubMed: 29019978]
18. Kamau A, et al. Malaria infection, disease and mortality among children and adults on the coast of Kenya. *Malar J*. 2020; 19 :210. doi: 10.1186/s12936-020-03286-6 [PubMed: 32552891]
19. Plummer M. Penalized loss functions for Bayesian model comparison. *Biostatistics*. 2008; 9 :523–539. DOI: 10.1093/biostatistics/kxm049 [PubMed: 18209015]
20. Carneiro I, et al. Age-patterns of malaria vary with severity, transmission intensity and seasonality in sub-Saharan Africa: a systematic review and pooled analysis. *PLoS One*. 2010; 5 :e8988 doi: 10.1371/journal.pone.0008988 [PubMed: 20126547]
21. Okiro EA, et al. Age patterns of severe paediatric malaria and their relationship to *Plasmodium falciparum* transmission intensity. *Malar J*. 2009; 8 :4. doi: 10.1186/1475-2875-8-4 [PubMed: 19128453]

22. Roca-Feltrer A, et al. The age patterns of severe malaria syndromes in sub-Saharan Africa across a range of transmission intensities and seasonality settings. *Malar J.* 2010; 9 :282. doi: 10.1186/1475-2875-9-282 [PubMed: 20939931]
23. Gupta S, Day KP. A theoretical framework for the immunoepidemiology of *Plasmodium falciparum* malaria. *Parasite Immunol.* 1994; 16 :361–370. DOI: 10.1111/j.1365-3024.1994.tb00361.x [PubMed: 7970875]
24. Gupta S, et al. Parasite virulence and disease patterns in *Plasmodium falciparum* malaria. *Proc Natl Acad Sci USA.* 1994; 91 :3715–3719. DOI: 10.1073/pnas.91.9.3715 [PubMed: 8170975]
25. Griffin JT, et al. Gradual acquisition of immunity to severe malaria with increasing exposure. *Proc R Soc B.* 2015; 282 20142657 doi: 10.1098/rspb.2014.2657
26. Gupta S, Snow RW, Donnelly C, Newbold C. Acquired immunity and postnatal clinical protection in childhood cerebral malaria. *Proc R Soc B.* 1999; 266 :33–38. DOI: 10.1098/rspb.1999.0600
27. Gupta S, Snow RW, Donnelly CA, Marsh K, Newbold C. Immunity to noncerebral severe malaria is acquired after one or two infections. *Nat Med.* 1999; 5 :340–343. DOI: 10.1038/6560 [PubMed: 10086393]
28. Mogeni P, et al. Age, spatial, and temporal variations in hospital admissions with malaria in Kilifi County, Kenya: a 25-year longitudinal observational study. *PLoS Med.* 2016; 13 e1002047 doi: 10.1371/journal.pmed.1002047 [PubMed: 27352303]
29. Trape JF, et al. The rise and fall of malaria in a west African rural community, Dielmo, Senegal, from 1990 to 2012: a 22 year longitudinal study. *Lancet Infect Dis.* 2014; 14 :476–488. DOI: 10.1016/S1473-3099(14)70712-1 [PubMed: 24813159]
30. Alonso PL. The role of mass drug administration of antimalarials. *Am J Trop Med Hyg.* 2020; 103 (suppl 2) :1–2. DOI: 10.4269/ajtmh.20-0729
31. Bennett A, et al. A longitudinal cohort to monitor malaria infection incidence during mass drug administration in Southern Province, Zambia. *Am J Trop Med Hyg.* 2020; 103 :54–65. DOI: 10.4269/ajtmh.19-0657 [PubMed: 32618245]
32. Galatas B, et al. A multiphase program for malaria elimination in southern Mozambique (the Magude project): A before-after study. *PLoS Med.* 2020; 17 e1003227 doi: 10.1371/journal.pmed.1003227 [PubMed: 32797101]
33. Mousa A, et al. The impact of delayed treatment of uncomplicated *P. falciparum* malaria on progression to severe malaria: A systematic review and a pooled multicentre individual-patient meta-analysis. *PLoS Med.* 2020; 17 e1003359 doi: 10.1371/journal.pmed.1003359 [PubMed: 33075101]
34. Paton RS. Replication Data for: Malaria infection and severe disease risks in Africa (Version 2.0). Harvard Dataverse. 2021; doi: 10.7910/DVN/XGDB3K
35. Paton RS. Code for: Malaria infection and severe disease risks in Africa (Version 1.0). Zenodo. 2021; doi: 10.5281/zenodo.4778315
36. WHO. Severe Malaria. *Trop Med Int Health.* 2014; 19 (suppl 1) :7–131. DOI: 10.1111/tmi.12313_2 [PubMed: 25214480]
37. Scott JAG, et al. Profile: the Kilifi health and demographic surveillance system (KHDSS). *Int J Epidemiol.* 2012; 41 :650–657. DOI: 10.1093/ije/dys062 [PubMed: 22544844]
38. Smith DL, Guerra CA, Snow RW, Hay SI. Standardizing estimates of the *Plasmodium falciparum* parasite rate. *Malar J.* 2007; 6 :131. doi: 10.1186/1475-2875-6-131 [PubMed: 17894879]
39. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing; 2020. www.R-project.org/
40. Plummer, M. In: Hornik, K; Leisch, F; Zeileis, A, editors. JAGS: A program for analysis of Bayesian graphical models using Gibbs sampling; Proceedings of the 3rd International Workshop on Distributed Statistical Computing (DSC 2003); 2003. www.r-project.org/conferences/DSC-2003/Proceedings/Plummer.pdf
41. Berkley JA, et al. Bacteremia among children admitted to a rural hospital in Kenya. *N Engl J Med.* 2005; 352 :39–47. DOI: 10.1056/NEJMoa040275 [PubMed: 15635111]
42. Bejon P, et al. Defining childhood severe falciparum malaria for intervention studies. *PLoS Med.* 2007; 4 e251 doi: 10.1371/journal.pmed.0040251 [PubMed: 17713980]

43. Marsh K, et al. Indicators of life-threatening malaria in African children. *N Engl J Med.* 1995; 332 :1399–1404. DOI: 10.1056/NEJM199505253322102 [PubMed: 7723795]
44. Njuguna P, et al. Observational study: 27 years of severe malaria surveillance in Kilifi, Kenya. *BMC Med.* 2019; 17 :124. doi: 10.1186/s12916-019-1359-9 [PubMed: 31280724]
45. Gething PW, et al. A new world malaria map: *Plasmodium falciparum* endemicity in 2010. *Malar J.* 2011; 10 :378. doi: 10.1186/1475-2875-10-378 [PubMed: 22185615]
46. Pull J, Grab B. A simple epidemiological model for evaluating the malaria inoculation rate and the risk of infection in infants. *Bull World Health Organ.* 1974; 51 :507–516. [PubMed: 4549501]
47. Mappin B, et al. Standardizing *Plasmodium falciparum* infection prevalence measured via microscopy versus rapid diagnostic test. *Malar J.* 2015; 14 :1–10. DOI: 10.1186/s12936-015-0984-9 [PubMed: 25557741]
48. Ackerman H, et al. The effect of blood transfusion on outcomes among African children admitted to hospital with *Plasmodium falciparum* malaria: a prospective, multicentre observational study. *Lancet Haematol.* 2020; 7 :e789–e797. DOI: 10.1016/S2352-3026(20)30288-X [PubMed: 33091354]
49. Anyona SB, et al. Cyclooxygenase-2 haplotypes influence the longitudinal risk of malaria and severe malarial anemia in Kenyan children from a holoendemic transmission region. *J Hum Genet.* 2020; 65 :99–113. DOI: 10.1038/s10038-019-0692-3 [PubMed: 31664161]
50. Ong'echa JM, et al. Parasitemia, anemia, and malarial anemia in infants and young children in a rural holoendemic *Plasmodium falciparum* transmission area. *Am J Trop Med Hyg.* 2006; 74 :376–385. DOI: 10.4269/ajtmh.2006.74.376 [PubMed: 16525094]
51. Akech S, et al. The Clinical Profile of Severe Pediatric Malaria in an Area Targeted for Routine RTS, S/AS01 Malaria Vaccination in Western Kenya. *Clin Infect Dis.* 2020; 71 :372–380. DOI: 10.1093/cid/ciz844 [PubMed: 31504308]
52. Irimu G, et al. Approaching quality improvement at scale: a learning health system approach in Kenya. *Arch Dis Child.* 2018; 103 :1013–1019. DOI: 10.1136/archdischild-2017-314348 [PubMed: 29514814]
53. Mpimbaza A, et al. Admission risk score to predict inpatient pediatric mortality at four public hospitals in Uganda. *PLoS One.* 2015; 10 e0133950 doi: 10.1371/journal.pone.0133950 [PubMed: 26218274]
54. Mpimbaza A, et al. The age-specific incidence of hospitalized paediatric malaria in Uganda. *BMC Infect Dis.* 2020; 20 :503. doi: 10.1186/s12879-020-05215-z [PubMed: 32660434]
55. Nadjm B, et al. Blood glucose as a predictor of mortality in children admitted to the hospital with febrile illness in Tanzania. *Am J Trop Med Hyg.* 2013; 89 :232–237. DOI: 10.4269/ajtmh.13-0016 [PubMed: 23817332]
56. Muthui K, et al. Gametocyte carriage in an era of changing malaria epidemiology: a 19-year analysis of a malaria longitudinal cohort. *Wellcome Open Res.* 2019; 4 :66. doi: 10.12688/wellcomeopenres.15186.1 [PubMed: 31223663]
57. Wamae K, et al. Transmission and age impact the risk of developing febrile malaria in children with asymptomatic *Plasmodium falciparum* parasitemia. *J Infect Dis.* 2019; 219 :936–944. DOI: 10.1093/infdis/jiy591 [PubMed: 30307567]
58. Were V, et al. Trends in malaria prevalence and health related socioeconomic inequality in rural western Kenya: results from repeated household malaria cross-sectional surveys from 2006 to 2013. *BMJ Open.* 2019; 9 e033883 doi: 10.1136/bmjopen-2019-033883
59. Kanya MR, et al. Malaria transmission, infection, and disease at three sites with varied transmission intensity in Uganda: implications for malaria control. *Am J Trop Med Hyg.* 2015; 92 :903–912. DOI: 10.4269/ajtmh.14-0312 [PubMed: 25778501]
60. Staedke SG, et al. The PRIME trial protocol: evaluating the impact of an intervention implemented in public health centres on management of malaria and health outcomes of children using a cluster-randomised design in Tororo, Uganda. *Implement Sci.* 2013; 8 :114. doi: 10.1186/1748-5908-8-114 [PubMed: 24079295]
61. Ishengoma S, et al. Trends of *Plasmodium falciparum* prevalence in two communities of Muheza district North-eastern Tanzania: correlation between parasite prevalence, malaria interventions and

- rainfall in the context of re-emergence of malaria after two decades of progressively declining transmission. *Malar J.* 2018; 17 :252. doi: 10.1186/s12936-018-2395-1 [PubMed: 29976204]
62. Bernard J, et al. Equity and coverage of insecticide-treated bed nets in an area of intense transmission of *Plasmodium falciparum* in Tanzania. *Malar J.* 2009; 8 :65. doi: 10.1186/1475-2875-8-65 [PubMed: 19371415]

Summary

The risk and age-pattern of severe malaria can be predicted by the quantity of parasite exposure in a given community.




Figure 1. Relationship between the rate of admissions of severe malaria (combination of severe malaria anaemia, respiratory distress and cerebral malaria) and community parasite prevalence ($PfPR_{2-10}$).

The median fit for the Bayesian regression model is denoted by the thick black line, with 95% and 99% highest density intervals in dark and light blue, respectively. Gray points and vertical 95% HDIs denote the model-estimated admission rates; intervals were not plotted for site periods in which a formal diagnoses of malaria phenotypes were available for all patients. The conditions of admitted malaria patients without a specific diagnosis of SMA, RD, or CM were stochastically diagnosed in submodels on the basis of other

indicative symptoms. Horizontal intervals represent the uncertainty in parasite prevalence calculated from a model that age-standardizes parasite prevalence to the 2-to-10-year age range while accounting for sample size and correcting for the diagnostic method (corrected rapid diagnostic test (RDT) surveys are indicated by closed points, microscopy by open circles).




Figure 2. Relationship between the admission rate of individual severe malaria phenotypes and community-based parasite prevalence.

Median regression model fits are denoted by the thick black line, with 95% and 99% highest density intervals in dark and light blue, respectively. **(A)** Nonlinear relationship between rates of SMA and $PfPR_{2-10}$. **(B)** shows the log-linear relationship between rates of RD and $PfPR_{2-10}$. **(C)** constant rate of CM for all values of $PfPR_{2-10}$. We modelled uncertainty in the admission rates of severe malaria anaemia and respiratory distress using a method akin to that used for the composite measure in Fig. 1. Because there were no alternative definitions of CM, uncertainty in admission rates was not considered (and therefore no vertical intervals were present). Uncertainty in community parasite prevalence was standardized to the 2-to-10-year age range, with a further correction for diagnostic method (corrected RDT surveys are shown as closed points, microscopy as open points).




Figure 3. Changes in age-specific admission rate per 1000 children p.a. of severe malaria phenotypes with parasite prevalence.

(A) Prediction surface for the model estimated rates of severe malaria for each month of childhood between 3 months and 9 years. The white arrow and 95% highest density intervals show the estimated increase in the most frequent age of admission with decreasing parasite prevalence. The dark blue rectangle denotes the estimated cutoff below a parasite rate of ~ 15.9% (14.1 to 17.6), below which admissions are relatively rare and can be adequately described as stochastic outcomes with age. It should be noted that this cutoff is sensitive to the amount of data available to characterise the age distribution of rare events; it is possible that our dataset lacks the requisite sensitivity to detect age dependence in severe malaria admissions at lower parasite rates. The most frequent age of admission increases with parasite prevalence, whereas the concomitant reductions in malaria incidence largely offset the shift of the burden onto other age classes. For each 25% increase in community $PfPR_{2-10}$, the age-dependent model predicted a doubling of admissions (2.05; HDI: 1.62 to 2.65); this agrees with the estimated increase for the age invariant model (2.06; HDI: 1.58 to 2.73). (B) The surface shown in (A) is presented as binned community parasite prevalence, including the associated 95% HDIs. The age dependence in admissions of severe malaria was modelled as a continuous process using a gamma distribution; the same diagnostic and community parasite rate submodels used in the age invariant model were also used here. A random effect for each site (on the admission rate) helped to account for sites with anomalously high or low rates of severe malaria for the corresponding estimate of community parasite prevalence.